share_log

藥明生物：截至2024年6月30日止股份發行人的證券變動月報表

WUXI BIO: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2024

Hong Kong Stock Exchange ·  Jul 4 08:21
Summary by Moomoo AI
藥明生物（药明生物技术有限公司）於2024年7月4日向香港交易及結算所有限公司提交了截至2024年6月30日的證券變動月報表。報告顯示，公司的法定/註冊股本結存維持在6,000,000,000美元，每股面值為USD1/120,000，總額為50,000美元。已發行股份（不包括庫存股份）從上月底的4,262,481,929股減少至4,153,165,949股，減少了109,315,980股。該變動主要是由於公司於2024年6月11日以每股21.31港幣的價格購回並註銷了109,868,000股普通股，以及於同日購回了1,810,000股尚未註銷的普通股。此外，報告還提到了股份期權計劃下的行使情況，以及受限制股份獎勵計劃和全球合夥人計劃下的股份獎勵計劃授出的股份。所有證券發行或庫存股份出售或轉讓均已獲得董事會正式授權批准，並遵守所有適用的上市規則、法律及其他監管規定。
藥明生物（药明生物技术有限公司）於2024年7月4日向香港交易及結算所有限公司提交了截至2024年6月30日的證券變動月報表。報告顯示，公司的法定/註冊股本結存維持在6,000,000,000美元，每股面值為USD1/120,000，總額為50,000美元。已發行股份（不包括庫存股份）從上月底的4,262,481,929股減少至4,153,165,949股，減少了109,315,980股。該變動主要是由於公司於2024年6月11日以每股21.31港幣的價格購回並註銷了109,868,000股普通股，以及於同日購回了1,810,000股尚未註銷的普通股。此外，報告還提到了股份期權計劃下的行使情況，以及受限制股份獎勵計劃和全球合夥人計劃下的股份獎勵計劃授出的股份。所有證券發行或庫存股份出售或轉讓均已獲得董事會正式授權批准，並遵守所有適用的上市規則、法律及其他監管規定。
Wuxi Bio (Wuxi Biologics Cayman Inc.) submitted a monthly securities change report as of June 30, 2024 to Hong Kong Exchanges and Clearing Limited on July 4, 2024. The report indicated that the company's legal/registered share capital balance remained at USD 6,000,000,000 with a par value of USD 1/120,000 per share, totaling USD 50,000. The number of issued shares (excluding treasury shares) decreased from 4,262,481,929 shares at the end of last month to 4,153,165,949 shares, a decrease of 109,315,980 shares. The change was mainly due to the company's repurchase and cancellation of 109,868,000 ordinary shares at a price of HKD 21.31 per share on June 11, 2024, as well as the repurchase of 1,810,000 ordinary shares that have not been cancelled on the same day. In addition, the report also mentioned the...Show More
Wuxi Bio (Wuxi Biologics Cayman Inc.) submitted a monthly securities change report as of June 30, 2024 to Hong Kong Exchanges and Clearing Limited on July 4, 2024. The report indicated that the company's legal/registered share capital balance remained at USD 6,000,000,000 with a par value of USD 1/120,000 per share, totaling USD 50,000. The number of issued shares (excluding treasury shares) decreased from 4,262,481,929 shares at the end of last month to 4,153,165,949 shares, a decrease of 109,315,980 shares. The change was mainly due to the company's repurchase and cancellation of 109,868,000 ordinary shares at a price of HKD 21.31 per share on June 11, 2024, as well as the repurchase of 1,810,000 ordinary shares that have not been cancelled on the same day. In addition, the report also mentioned the exercise of stock options under the share option scheme, and the issuance of shares under the restricted share award plan and the global partner plan's share award plan. All securities issuance or sale of treasury shares or transfer has been officially authorized and approved by the board of directors, and complied with all applicable listing rules, laws and other regulatory requirements.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more